This paper presents an investigation into a mathematical model of cancer tumour growth and response with chemotherapy and immunotherapy treatments. d'Onofrio and co-workers [1] [2] [3] developed a model to predict and control cancer tumour growth based on cell functions and effects of chemotherapy and immunotherapy. Several design objectives and constraints were used to obtain optimal drug scheduling. These included (i) maximizing tumour cell killing, (ii) tolerable drug concentration, (iii) tolerable body temperature rise and (iv) normal increase of vasculature cell at the end of treatment regime [1] . This paper, initially, implements the model in a simulation environment and then analyzes it with several drug doses that maximize killing of cancerous cells and increase normal vasculature cells during and after treatment period. Then a number of doses have been designed heuristically to improve aforementioned treatment objectives and to analyze the effects of chemotherapy and immunotherapy further. The designed doses show significant improvement in terms of cancerous cell killing with a normal recovery of vasculature cell after the treatment period. This paper also presents an investigation into parameter sensitivity of the model that shows tumour response with different model parameters and drug doses.
I Introduction
Cancer is one of the major diseases of humanity. Cancer arises from a mutation of genes which are responsible for the correct reproduction of cells. The final result is a malignancy, a tumor, which grows uncontrolled and invasive. Classic treatments contain the removal of the tumour by surgery, radiotherapy, immunotherapy and also chemotherapy, which means infusion of drugs that inhibits or stops the growth of tumor cells [4] [5] . Chemotherapy, in general, affects non-tumor cells, a negative side effect, which has to be kept under control. Such therapies may be combined with additional therapies, like anti-angiogenesis, which has an effect on the blood vessel in the neighborhood of the tumor, or immunotherapy which aims at a stimulation of the patients' immune system [4] [5] . Particularly for medical treatments such as chemotherapy, immunotherapy, antiangiogenic therapy, and a combination of them, time and amount of drug infusion may be crucial, since the cell population undergo complex processes. As a result mathematical Modeling, simulation, and optimization have become an indispensable ingredient of research [3] [4] [5] [6] [7] [8] [9] . This paper presents an investigation into a mathematical model of cancer tumour growth and response with chemotherapy and immunotherapy treatments.
II. Cancer Chemotherapy Model
The cancer tumour model developed by d'Onofrio and coworkers [1] [2] is modification of Hahnfeldt model [10] .The model consists of two states, three control and eleven parameters in three parameter sets. It contains a combination of chemotherapy and immunotherapy. Model equations are stated below [3] : X o`( t)= x o (t) ln (x o (t)/x 1 (t)) Equation (1) represents tumour population x 0 after the treatment regime whereas volume of vasculature cell after treatment regime is expressed by equation (2) . Equation (3) and (4) represent applied immunotherapy and chemotherapy doses. Parameter sets of the model are shown in Table 1 . 
X 2` (t) = 0 (t) ---------------------------------------
X 3` (t) = 1 (t) --------------------------------------(3)
III. Implementation and Results
The whole model, as stated earlier, is implemented in Matlab/Simulink [11] environment where standard set of parameters, as indicated in Table 1 is used. Matlab/Simulink is chosen as it offers easier implementation and visualization of response of such system. It is to be noted that following constraints in relation to drug doses must be maintained while implementing the model. Case 2: Maximum amount of chemo & immunotherapy dose is applied at first, chemo dose is reduced to 0 after 2 days but immunotherapy is continued for 4 days. Figure 3 shows chemotherapy and immunotherapy drug doses and corresponding responses of tumour and vasculature cells with Case 2. Tumour cell volume is reduced rapidly to 75% within two days as an effect of chemotherapy and then gradually to 8000mm 3 due to continuation of immunotherapy. Vasculature cell volume reduces to 5000mm 3 from 14000mm 3 due to both high chemo and immune dose. Then due to absence of chemo dose vasculature cell goes to the recovery phase. about 50% of its initial value very rapidly and then gradually decreased more than 30%. Tumour cell volume also reduced slightly due to immuno therapy effect. When high dose of chemotherapy is applied there is a rapid reduction to 4000mm 3 , about 67% reduction is achieved. Immunotherapy dose is increased to 25mg at the very beginning of the treatment and then gradually increased up to 50mg. Prior to immunotherapy the vasculature cell volume is increased from 5000 mm 3 to 9000mm 3 and then decreased from 9000 mm 3 to 4000 mm 3 as the response of immunotherapy-reduction rate is 55%. Such a reduction of vasculature cell also causes the reduction of tumour cell volume from 14000mm 3 to 11000mm 3 i.e. 22% reduction without any chemotherapy.
Then before 2 days of the cycle the maximum dose of chemotherapy is applied and cancerous cell volume reduces to 8000mm 3 which is 56% of the initial value. It means another 22% reduction in 2 days for maximum chemo dose. At the end The vasculature cell volume reduction is 77%. Then after 2 days the maximum dose of chemotherapy is applied and cancerous cell volume reduces to 4000 mm 3 which is 28% of the initial value. At the end immunotherapy is decreased to zero to facilitate vasculature cell recovery phase.
Case 6: Figure 6 shows chemotherapy and immunotherapy drug doses and corresponding responses of tumour and vasculature cells with Case 6. It is observed that, cancerous cell volume reduces from 12000 mm 3 to 4000mm 3 , i.e. reduction is about 67%. Immunotherapy is decreased from 75mg to 50mg and then slowly increased up to 60mg. Due to the high dose of both the therapy vasculature cell volume decreased from 14000mm 3 to 6000mm 3 : reduction is 57% at the beginning and finally reaches to 2000 mm 3 i.e reduction is 87% from initial value. Such a reduction of vasculature cell also causes the rapid reduction of tumour cell volume. The end value of vasculature cell recovery is 4000mm 3 . Performance measures of different treatment cases are summarized in Table  3 . 
Remarks
In Case 3, there is a maximum reduction of tumour cell volume at the cost of high chemo dose. It also affects the vasculature cells to a great extent. Recovery to the normal state requires a long period. In case 4, although reduction is 43%, it requires 40% chemotherapy compared to Case 3. Vasculature cells are not too much and there is a normal increase of volume at the end compared to prior the treatment. So Case 4 can be considered most suitable to apply.
IV. Heuristically Design Drug Doses and Their Effects
Since Case 4 delivers the best results, the scheduling can be modified to achieve even better response. immunotherapy doses are 150mg and 313mg respectively. Figure 8 shows drug doses and response of model with Case 7. After the treatment period tumour volume decrease from 14000mm 3 to 6300mm 3 .There is natural increase of vasculature cell volume from 6000mm 3 to 6500mm 3 . It can be explained as, since there is a rest period of chemotherapy within the treatment schedule, it helps the antibody cells and vasculature cells to recovery from toxic effects of chemo medicine. and 5 th day there is a step wise decrease to zero. For immunotherapy there is a gradual increase. Cumulative chemotherapy and immunotherapy doses are 155mg and 313mg respectively. After the treatment period tumour volume decrease from 14000mm 3 to 4000mm 3 and vasculature cell volume are reduced from 4000mm 3 to 7000mm 3 . All results are shown in Table 4 . From Table 4 , it is observed that for a fixed immunotherapy by applying a well scheduled chemotherapy it is possible to obtain maximum amount of reduction of tumour volume with very little effect on normal body cell. In Case 8, chemotherapy is 40mg lower than the first case but tumour volume is reduced 18% more because of well scheduling. At the same time vasculature cell volume is in increasing trend by a well margin showing better recovery. Table 1 , are used. It is also noted that, values of parameters remained unchanged for the whole period to observe the effectiveness of drugs on cancer tumour. It may be mentioned that the predefined set of parameters correspond to a specific physiological condition and drug type under investigation. Table 5 . The maximum tumour cell reduction is obtained with 0.07 which is reduced from 15000mm 3 to 9000 mm 3 i.e. 40%. At the same time vasculature cell growth is also suppressed by tumour growth rate. 
VI. Conclusion
This paper has presented a design and investigation into a mathematical model of cancer tumour response with chemotherapy and immunotherapy treatments. Optimal drug dosages and scheduling for chemotherapy and immunotherapy as designed by d'Onofrio and co-workers using several design objectives and constraints have been tested to observe the response of tumour during and after the treatment. Moreover, a number of dosages, both for chemotherapy and immunotherapy, have been designed based on heuristic method in the light of earlier dosages to improve the treatment further. It is observed that instead of applying a high dose for a long time, periodic application of high dose yields better results with regard to tumour volume reduction. The optimal treatment yields a tumour volume 71% smaller than the initial stage. In this paper an investigation into parameter sensitivity of the model has also been presented that helps to predict the effect of drugs on different types of cancer cell as well as effect of different types of drugs on tumour and vasculature cells.
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